Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Neurobiol Dis. 2016 Jan 27;89:1–9. doi: 10.1016/j.nbd.2016.01.020

Figure 1. CuATSM treatment and survival of SODG93AxCCS mice.

Figure 1

The dosing schedule with CuATSM (30 mg/kg given twice a day) is shown on the top as maroon bars. (A) Kaplan-Meier plot of ALS-survival probability of SODG93AxCCS mice receiving either no treatment (black dashed line, n=15), CuATSM treatment stopped at weaning (blue, n=6), treatment stopped at weaning and restarted at symptom onset (dashed grey-blue, n=7), and continuous CuATSM treatment (black, n=17). Censored mice are shown as black circles or grey-blue diamonds. (B) Weights with standard deviations for the three treated groups are show using the same symbols as in 1A. Only means are shown after age 600 days because three or fewer mice survived.